NASDAQ:LMNL Liminal BioSciences (LMNL) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free LMNL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.48▼$8.5050-Day Range$8.38▼$8.5052-Week Range$3.10▼$8.50Volume5,000 shsAverage Volume63,470 shsMarket Capitalization$26.35 millionP/E Ratio29.31Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Liminal BioSciences alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Liminal BioSciences Stock (NASDAQ:LMNL)Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.Read More Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. LMNL Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comLIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPSeptember 19, 2023 | finanznachrichten.deLiminal BioSciences Inc.: LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.September 19, 2023 | msn.comLiminal BioSciences gets final order for the Structured Alpha takeoverSeptember 19, 2023 | finance.yahoo.comLIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPSeptember 15, 2023 | finance.yahoo.comLIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPSeptember 12, 2023 | finanznachrichten.deLiminal BioSciences Inc.: LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULARSeptember 12, 2023 | finance.yahoo.comLIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULARApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.August 16, 2023 | msn.comLiminal BioSciences shareholders to vote on takeover deal Sept. 15August 16, 2023 | finance.yahoo.comLIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LPAugust 8, 2023 | finanznachrichten.deLiminal BioSciences Inc.: Liminal BioSciences Reports Second Quarter Financial Results 2023August 8, 2023 | finance.yahoo.comLiminal BioSciences Reports Second Quarter Financial Results 2023July 13, 2023 | prnewswire.comLimina BioSciences annonce la conclusion d'un accord avec Structured Alpha LPJuly 13, 2023 | finance.yahoo.comLiminal (LMNL) Up 40% on Buyout Offer From Majority ShareholderJuly 12, 2023 | marketwatch.comLiminal BioSciences Accepts $8.50 a Share Buyout Offer From Structured AlphaJuly 12, 2023 | msn.comLMNL Skyrockets on Acquisition by Structured AlphaJuly 12, 2023 | benzinga.comLiminal BioSciences Stock Gains0% Today - Here's Why?July 12, 2023 | finanznachrichten.deLiminal BioSciences Inc.: Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LPJuly 12, 2023 | msn.comLiminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset ManagementJuly 12, 2023 | finance.yahoo.comLiminal BioSciences Announces Arrangement Agreement with Structured Alpha LPJune 5, 2023 | finanznachrichten.deLiminal BioSciences Inc.: Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of ShareholdersJune 5, 2023 | finance.yahoo.comLiminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of ShareholdersJune 2, 2023 | finanznachrichten.deLiminal BioSciences Inc.: Liminal BioSciences Provides R&D UpdateJune 2, 2023 | finance.yahoo.comLiminal BioSciences Provides R&D UpdateMay 9, 2023 | finanznachrichten.deLiminal BioSciences Inc.: Liminal BioSciences Reports First Quarter Financial Results 2023May 9, 2023 | msn.comLiminal BioSciences reports resultsSee More Headlines Receive LMNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Liminal BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LMNL CUSIPN/A CIK1351172 Webwww.liminalbiosciences.com Phone1-450-781-0115Fax1-450-781-4477Employees251Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.29 Trailing P/E Ratio29.31 Forward P/E RatioN/A P/E GrowthN/ANet Income$380,000.00 Net Margins248.35% Pretax Margin-5,729.40% Return on Equity-88.44% Return on Assets-64.15% Debt Debt-to-Equity Ratio0.02 Current Ratio2.78 Quick Ratio2.78 Sales & Book Value Annual Sales$310,000.00 Price / Sales85.00 Cash FlowN/A Price / Cash FlowN/A Book Value$8.97 per share Price / Book0.95Miscellaneous Outstanding Shares3,100,000Free Float3,036,000Market Cap$26.35 million OptionableNot Optionable Beta1.03 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Bruce Pritchard BA (Age 49)CA, FIOD, Chief Exec. Officer Comp: $698.94kMr. Patrick Sartore (Age 48)Pres Comp: $613.82kDr. Gary J. Bridger Ph.D. (Age 60)Interim Chief Scientific Officer & Non-Independent Director Comp: $264.69kMs. Marie Iskra L.L.B. (Age 46)Corp. Sec. & Gen. Counsel Comp: $435.82kMs. N. Nicole Rusaw C.A. (Age 50)C.P.A., CA, CPA, HBACC, Chief Financial Officer Shrinal InamdarMang. of Investor Relations & CommunicationsDr. Steven J. BurtonPres of Prometic Bioseparations LtdMore ExecutivesKey CompetitorsQilian International Holding GroupNASDAQ:QLIDURECTNASDAQ:DRRXIterum TherapeuticsNASDAQ:ITRMSol-Gel TechnologiesNASDAQ:SLGLForte BiosciencesNASDAQ:FBRXView All Competitors LMNL Stock Analysis - Frequently Asked Questions How were Liminal BioSciences' earnings last quarter? Liminal BioSciences Inc. (NASDAQ:LMNL) issued its quarterly earnings data on Monday, November, 15th. The company reported $27.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.80) by $30.20. The firm earned $0.14 million during the quarter, compared to analysts' expectations of $0.02 million. Liminal BioSciences had a net margin of 248.35% and a negative trailing twelve-month return on equity of 88.44%. When did Liminal BioSciences' stock split? Liminal BioSciences shares reverse split before market open on Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Liminal BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Liminal BioSciences investors own include ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Aeterna Zentaris (AEZS), American Cannabis (AMMJ), Bionano Genomics (BNGO), Bergio International (BRGO), CBL & Associates Properties (CBL) and Auxly Cannabis Group (CBWTF). This page (NASDAQ:LMNL) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminal BioSciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
